Drugs / EP-104GI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05608681 | Mar 2023 → Dec 2026 expected | eosinophilic esophagitis | Eupraxia Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP-104GI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05608681 ↗ |
| Route | Other | “submucosal injections of EP-104GI administered during an EGD procedure” NCT05608681 ↗ |